Smith+Nephew (LSE:SN,NYSE:SNN), the global medical technology business, today announced outstanding clinical results for its total hip arthroplasty (THA) portfolio in both the National Joint Registry for England, Wales and Northern Ireland (NJR) and the the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). The data confirms Smith+Nephew’s POLAR3™ Total Hip Solution – a proprietary combination of its POLARSTEM™ Cementless Stem, R3™ Acetabular System and OXINIUM™ Technology has the top performing cementless construct components for THA.
The NJR 2020 annual report showed the latest implant survivorship figures in total joint arthroplasty in which Smith+Nephew’s POLARSTEM and R3 demonstrated:
The highest implant survivorship (98.46%) of all cementless hip constructs at ten years1
72% lower revision risk compared to the class average for cementless hip combinations at ten years1
Furthermore, the recently issued AOANJRR 2020 annual report showed that Smith+Nephew’s proprietary OXINIUM Technology (ceramicised metal on XLPE) continued to have the lowest revision rate of all hip bearing combinations at fifteen years2, and:
From one year, significantly reduces the risk of revision compared to Metal/XLPE by 39–41%2
Demonstrated 94.5% survivorship at 15 years2
“I have been using the combination of POLAR3 for ten years now and have been impressed with the results, but even more importantly, so have my patients,” said Mr. Philip Roberts, Consultant Orthopaedic Surgeon at University Hospitals of North Staffordshire, NHS Trust. “It’s very reassuring when a surgeon can say to a patient that the implant being used has such a high-performance record on the NJR here in the UK – and across the world – with other surgeons and patients. It’s that bond of trust between patient and surgeon that POLAR3 gives you, and that is priceless.”
“There are now four prominent registries with mid- to long-term data confirming that our OXINIUM Technology has the highest survivorship,” said Vasant Padmanabhan, President Global R&D for Smith+Nephew.3,4 “With these milestone results, orthopaedic surgeons can be more confident than ever in recommending POLAR3 as best performing cementless hip construct and bearing combination on the market today to their patients.”
Source: Company Press Release
